Fingerprint
Dive into the research topics of 'Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: A randomised, placebo-controlled, phase 2b study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: A randomised, placebo-controlled, phase 2b study
William J. Sandborn, Jean Frédéric Colombel, Subrata Ghosh, Bruce E. Sands, Gerald Dryden, Xavier Hébuterne, Rupert W. Leong, Brian Bressler, Thomas Ullman, Peter L. Lakatos, Walter Reinisch, Li An Xu, Allison Luo
Research output: Contribution to journal › Article › peer-review
50
Scopus
citations